Cannabis & Hemp Stocks Investment Tools – Schedule Demo Now!

OWC jumps 27% on news it will discuss myeloma drug at MJBizCon

OWC jumps 27% on news it will discuss myeloma drug at MJBizConTel Aviv-based OWC Pharma, a developer of cannabinoid-based therapies for various disorders, recently announced successful tests in October of its new delivery formulation for Multiple Myeloma therapy. This week, when it announced it will attend the 2018 MJBizCon (Marijuana Business Conference) in Las Vegas, on November 14-16, 2018, its stock price jumped 25% in two days.

Multiple Myeloma is an incurable blood cancer that effects 30,000 new patients a year in the USA alone. Cannabis-based therapies could be a new frontier in fighting the disease. According to OWC CEO Dr. Stanley Hirsch, “this potentially moves cannabis from being a cancer palliative to becoming a cancer therapeutic.”

MJBizCon, is a conference that aims to drive cannabis business deals. There will be 20,000+ cannabis professionals and 1,000+ exhibitors at the event. OWC will hold meetings with investors, researchers and business partners there.

In the recent tests of its new delivery formulation for Multiple Myeloma therapy, OWC administered OWC-1808 in vivo into animals and it was found to be safe and tolerable. The formulation will allow delivery of high doses of CBD and THC with good bioavailability.

To schedule a meeting or learn more about OWC research, contact Ms. Miri Chen at miri.chen@owcpharma.com

OWC, through its Israeli subsidiary, One World Cannabis Ltd., conducts research to develop cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. It is s also developing delivery systems of medical cannabis. All OWC research is conducted at Israeli hospitals and scientific institutions.

Sources

OWC website

OWC press release

OWC press release

OWC jumps 27% on news it will discuss myeloma drug at MJBizCon

About Cannin Investment Group: Your Pot Stocks Experts

Cannin is your trusted resource for pot stocks. Our global team of experts evaluates all emerging pot stock investing opportunities. We aggregate hundreds of hours of research and provide tips on the best pot stock investments for 2020. 

Use Cannin as your resource for:

Is it too late to invest in pot stocks? No! This is the perfect time to invest.

Market analysts expect the legal cannabis industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in pot stocks is now. Are you looking to buy stock in pot companies for 2020? Interested in emerging penny pot stocks? Looking for the best Canadian pot stocks to invest in? We can help.

Are you interested in pot stocks like Curaleaf, Trulieve, Aurora Cannabis, or Canopy Growth?

Predict price movements of pot stocks several hours in advance with our proprietary algorithmic stock trading software.

  • +25% Gains in 2020
  • +49.8% Gains in 2019
  • 108% Backtested since 2012

We’re so confident you’ll love our algotrading pot stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.

Profit from the best pot stocks – we’ll show you how at cannin.com.

Marijuana Stocks, Pot Stocks, Algorithmic Stock Trading, Penny Hemp Stocks